Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism

BMC Nephrology

Research Article

Kerry Cooper¹  Vasily Belozeroff¹  John Caloyeras¹  Deborah Brommage²  Brett Hauber³  Joshua Posner³ 

[1] Amgen, Thousand Oaks, CA, USA;National Kidney Foundation, New York, NY, USA;RTI Health Solutions, Offices Drive, Research Triangle Park, 200, Park, NC, USA;

关键词: Secondary hyperparathyroidism;    End-stage renal disease;    Discrete-choice experiment;    Conjoint analysis;   

DOI  :  10.1186/s12882-017-0665-8

 received in 2016-10-21, accepted in 2017-07-14,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundPatient engagement and patient-centered care are critical in optimally managing patients with end-stage renal disease (ESRD). Understanding patient preferences is a key element of patient-centered care and shared decision making. The objective of this study was to elicit patients’ preferences for the treatment of secondary hyperparathyroidism (SHPT) associated with ESRD using a discrete-choice experiment survey.MethodsClinical literature, nephrologist input, patient-education resources, and a patient focus group informed development of the survey instrument, which was qualitatively pretested before its administration to a broader sample of patients. The National Kidney Foundation invited individuals in the United States with ESRD who were undergoing hemodialysis to participate in the survey. Respondents chose among three hypothetical SHPT treatment alternatives (two medical alternatives and surgery) in each of a series of questions, which were defined by attributes of efficacy (effect on laboratory values and symptoms), safety, tolerability, mode of administration, and cost. The survey instrument included a best-worst scaling exercise to quantify the relative bother of the individual attributes of surgery. Random-parameters logit models were used to evaluate the conditional relative importance of the attributes.ResultsA total of 200 patients with ESRD completed the survey. The treatment attributes that were most important to the respondents were whether a treatment was a medication or surgery and out-of-pocket cost. Patients had statistically significant preferences for efficacy attributes related to symptom management and laboratory values, but placed less importance on the attributes related to mode of administration and side effects. The most bothersome attribute of surgery was the risk of surgical mortality.ConclusionsPatients with ESRD and SHPT who are undergoing hemodialysis understand SHPT and have clear and measurable treatment preferences. These results may help inform clinicians about patients’ preferences regarding treatment options for a common complication of ESRD.

【 授权许可】

CC BY   
© The Author(s). 2017